PsychoGenics Inc. Appoints David A. Lowe as Chief Scientific Officer and Executive Vice President of Research and Development

TARRYTOWN, N.Y.--(BUSINESS WIRE)--PsychoGenics Inc., announced the appointment of David A. Lowe, Ph.D., as Chief Scientific Officer (CSO) and Executive Vice President of Research and Development (EVP, R&D). This appointment reflects the Company’s growth and expansion into new areas of Central Nervous System (CNS) drug discovery and clinical development, and its continued commitment to the development of novel proprietary technologies to support internal and partnered drug discovery and translational research.